ABCL today
$11.95-$0.51 (-4.09%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $13.86
Key levels
Resistance$13.86
Resistance$12.58
Support$11.05
Support$9.57
Latest news & SEC filings
AnalystStoneX keeps Buy rating on AbCellera Biologics, lifts target to $15
AnalystStifel raises its price target for AbCellera Biologics
AnalystStifel keeps Buy rating on AbCellera Biologics, lifts target to $14
All ABCL news →About AbCellera
AbCellera is a biotechnology company that discovers and develops antibody-based drugs. It uses its technology platform to identify antibodies for its own pipeline and for partners, including pharmaceutical and biotech companies, nonprofits, and government organizations. The company operates in Canada and the United States, with drug candidates in preclinical and early clinical testing.
Based on the company's 10-K filed Feb 24, 2026.
Nasdaq · Healthcare
AbCellera Biologics Inc. (ABCL)
What Is the Price Target for ABCL?
SEPT Low Target
$11.00
SEPT Mid Target
$14.50
SEPT High Target
$30.00
Analyst Consensus
$14.50
Is ABCL a Buy or Sell Right Now?
Thesis
- •Revenue growing 160.6% YoY with ACCELERATING trend — accelerating momentum.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ABCL.
Start Free Trial →Is ABCL Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$12.75
25
Moat Score
NONE
4/9
Piotroski Score
5.8
Altman Z-Score
What Is Smart Money Doing with ABCL?
Insider Signal
BUYING
8 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Hayden Michael R | director | Buy | 53,613 | $570K | Aug 24, 2026 |
| Montalbano John S. | director | Buy | 10,000 | $110K | Aug 18, 2026 |
| Booth Andrew | officer | Buy | 37,200 | $384K | Aug 14, 2026 |
| Hayden Michael R | director | Buy | 46,387 | $481K | Aug 12, 2026 |
| Hayden Michael R | director | Sale | 50,000 | - | Aug 11, 2026 |
| Booth Andrew | officer | Buy | 250,000 | $48K | Jun 3, 2026 |
| Montalbano John S. | director | Buy | 20,000 | $95K | May 14, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ABCL Growth Story
Revenue YoY
160.6%
3yr Revenue CAGR
-46.3%
EPS Growth YoY
10.91%
FCF Growth YoY
6.9%
Revenue Trend
ACCELERATING
Dark Pool Trades for ABCL
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ABCL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 12:08:24 | $11.94 | 2,820 | $$34K | BUY |
| 09:00:06 | $11.88 | 1,000 | $$12K | SELL |
| 23:18:00 | $11.96 | 1,500 | $$18K | SELL |
| 22:06:59 | $12.09 | 1,038 | $$13K | BUY |
| 21:00:31 | $11.95 | 8,878 | $$106K | SELL |
5 dark pool trades shown · $$182K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for ABCL
PREVIEWSEPT Investing provides real-time options flow tracking for ABCL, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $19 | Dec 18 | 37 | $$45 | 3 | SWEEP |
| CALL | $19 | Dec 18 | 37 | $$15 | 1 | SWEEP |
| CALL | $19 | Dec 18 | 37 | $$75 | 5 | SWEEP |
| CALL | $19 | Dec 18 | 37 | $$15 | 1 | SWEEP |
| CALL | $19 | Dec 18 | 37 | $$15 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About ABCL
2 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for ABCL. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Smart Money Moves $VST — BURKE JAMES A | Sale $270K $ABCL — Hayden Michael R | Sale $570K $CRM — DONALD ARNOLD W | Sale $HYLN — Oxholm Jose Miguel | Sale $40K $INFQ — MAVERICK CAPITAL LTD | Sale $2.1...
Smart Money Moves $ABCL — Montalbano John S. | Sale $110K $LITE — Kim Jae | Sale $1.2M $TPL — HORIZON KINETICS ASSET MANAGEMENT LLC | Sale $0K $TALK — Braunstein Douglas L | Sale $TALK — Braunstein D...
Join 3,500+ traders discussing ABCL in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for AbCellera Biologics Inc. (ABCL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ABCL — frequently asked questions
What is ABCL stock price today?
AbCellera Biologics Inc. (ABCL) is at $11.95, down 4.09% (-$0.51) at the Nov 11, 2026 close.
Why is ABCL stock moving today?
Latest ABCL news — Nov 11, 2026: StoneX keeps Buy rating on AbCellera Biologics, lifts target to $15 · Nov 10, 2026: Stifel raises its price target for AbCellera Biologics
Why did ABCL stock move on Nov 9, 2026?
AbCellera Biologics shares rose 5.04% to close at $12.50 after the company reported a third-quarter loss of $0.13 per share, narrower than the $0.16 loss analysts expected, while revenue of $10.639 million topped the $8.416 million estimate. The stock traded between a low of $11.68 and a high of $12.74 on volume of 2,756,460 shares.
What is the ABCL price target?
The average analyst price target for ABCL is $14.50, ranging from $11 to $30, based on 8 analysts. Latest: StoneX maintains on Nov 11, 2026.
What do analysts rate ABCL?
Analyst ratings for ABCL: 0 Buy, 9 Hold, 0 Sell — consensus Hold.
Did ABCL beat earnings?
ABCL last reported on Nov 9, 2026: EPS -$0.13 vs -$0.16 expected — a beat of 18.8%.
Does ABCL pay a dividend?
ABCL does not currently pay a dividend.
What are ABCL support and resistance levels?
Support: $11.05, $9.57, $8.44. Resistance: $12.58, $13.86, $15.02.
What are insiders doing with ABCL?
Insider activity: BUYING, 8 buys and 0 sells in the last 90 days.
What is the latest news on ABCL?
Nov 11, 2026: StoneX keeps Buy rating on AbCellera Biologics, lifts target to $15 · Nov 10, 2026: Stifel raises its price target for AbCellera Biologics · Nov 10, 2026: Stifel keeps Buy rating on AbCellera Biologics, lifts target to $14